By Chris Wack

 

Addex Therapeutics Ltd. said its partner, Janssen Pharmaceuticals Inc., has received the U.S. Food and Drug Administration's Investigational New Drug approval to begin a Phase 2a proof of concept study for a treatment for patients with epilepsy.

The clinical-stage pharmaceutical company said the first patient is expected to be treated during the second quarter of 2021.

Addex said the multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 administration in patients with focal onset seizures with suboptimal response to levetiracetam.

The primary objective of the study is to evaluate the efficacy of JNJ-40411813 in combination with levetiracetam using a time-to-event endpoint.

Addex Therapeutics shares were up 65% to $17.79 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

January 21, 2021 06:28 ET (11:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.